Berger Montague Investigates Class Action Suit Against MoonLake Immunotherapeutics Following Major Financial Missteps
Berger Montague Investigates Class Action Against MoonLake Immunotherapeutics
In a significant development within the biotech and legal sectors, Berger Montague PC has announced its investigation into claims concerning MoonLake Immunotherapeutics (NASDAQ: MLTX). This comes following the filing of a class action lawsuit aimed at protecting the rights of investors who purchased shares in the company during the period from March 10, 2024, to September 29, 2025. The lawsuit has drawn considerable attention, particularly given the serious allegations made against MoonLake regarding its primary drug candidate, sonelokimab (SLK).
MoonLake Immunotherapeutics, based in Zug, Switzerland, is primarily focused on developing therapies for inflammatory diseases. The firm has made bold claims regarding the clinical superiority of SLK, leaning heavily on assertions that its unique Nanobody structure sets it apart from competing treatments. However, the lawsuit alleges that the corporation failed to disclose crucial information about SLK's effectiveness in comparison to an already approved drug, BIMZELX. The claim asserts that SLK targets the same molecular pathways as BIMZELX but does not offer any clear clinical advantage.
On September 28, 2025, the company revealed disappointing results from its Phase 3 clinical trials, which demonstrated that SLK did not reach the efficacy levels seen with BIMZELX. This revelation was described by analysts as
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.